Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

Belgian biotech firm ThromboGenics (Euronext Brussels: THR) says that the Final Early Benefit Assessment from the German Federal Joint Committee (G-BA) has concluded that its Jetrea (ocriplasmin) demonstrates significant added benefit for vitreomacular traction (VMT) patients with mild and moderate symptoms when compared with existing comparative treatment (watchful waiting).

The mild to moderate VMT population, as referred to by G-BA in its final assessment, represents the vast majority (94%) of the total patient population covered by the approved label.
The G-BA is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany. Since the introduction of the early benefit assessment procedure in Germany in January 2011, the G-BA has assessed more than 60 innovative new drugs. Jetrea  is, to-date, one of only six innovative medicines appraised by the G-BA to provide significant additional therapeutic benefits for patients, noted ThromboGenics.

Backs IQWiG recommendation